Disruptive Innovations US Speakers
Jeff S. Kasher, PhD
VP, Clinical Trial: Materials, Implementation and Transformation
Jeffrey S. Kasher, PhD, was named vice president, global clinical trial: materials, implementation and transformation in September 2012.
He received a bachelor of science degree in chemistry from Franklin & Marshall College (Lancaster, PA), a doctorate in pharmacology from the State University of New York (Syracuse) and a postdoctoral fellowship in physiology at Yale University School of Medicine.
Dr Kasher joined Lilly in 1986 as a senior pharmacologist in the department of drug metabolism and disposition where he made numerous contributions to the discovery and development of projects in the infectious disease therapeutic area. In 1992, he was named manager of pharmaceutical project management. Kasher had operational responsibility for the Zyprexa (olanzapine) heavyweight team from 1995 to 1998, successfully leading the late phase development, global submissions, and launches of the product. In 1998, he was named director of pharmaceutical products, where he helped establish Lilly’s product team organization.
Dr Kasher moved to Belgium in 2000 as the managing director for the research and development site in Mont Saint-Guibert. Upon his return to Indianapolis in 2003, he served as operations director and then executive director for discovery biology in Lilly Research Labs, leading the transformation of the division into therapeutically-focused drug hunting teams. Kasher served as the executive director of the osteoarthritis/rheumatoid arthritis platform team, leading the development of an integrated strategy for a portfolio of novel drug candidates.
Dr Kasher was named vice president and chief operating officer, global clinical development for Eli Lilly and Company in February 2007. He established and was accountable for the Lilly Clinical Development Organization which included Clinical Project Management, Regional Clinical Operations, Global Clinical Pharmacology & Diagnostics, Statistics, Scientific Communication, Data Science & Solutions, and 6 Sigma/Business Process Management/Critical Chain Project Management. In his current role he is responsible for the delivery of clinical studies and information in support of Lilly molecules. The primary responsibility is to patients and healthcare professionals who depend on our products and services today and in the future. Kasher has responsibility for Regional Clinical Operations, Global Clinical Pharmacology & Diagnostics, Clinical Trial Manufacturing & Material Services, 6 Sigma/Business Process Management/Critical Chain Project Management, and Clinical Development Innovation.